<DOC>
	<DOCNO>NCT01854567</DOCNO>
	<brief_summary>The study investigate time engraftment mesenchymal expand cord blood unit patient hematologic malignancy undergo transplantation myeloablative conditioning .</brief_summary>
	<brief_title>P3 Study Umbilical Cord Blood Cells Expanded With MPCs Transplantation Patients With Hematologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<criteria>Patient must one following : Acute myelogenous leukemia ( AML ) complete morphological remission study screen ( Complete Remission Incomplete Platelet Recovery ( CRp ) acceptable ) . Acute lymphoblastic leukemia ( ALL ) complete morphological remission study screen ( Complete Remission Incomplete Platelet Recovery ( CRp ) acceptable ) . NonHodgkin 's lymphoma ( NHL ) : High risk subject responsive disease first relapse . High risk include Burkitt 's Lymphoma extensive marrow involvement diagnosisprecluding autologous transplant . Hodgkin 's disease : High risk subject responsive disease first relapse . Minimum Karnofsky Scale Subject must weigh least 20 kg Up 65 year age Adequate major organ system function Pregnancy and/or lactate Suitable , 6/6 HLA match related sibling donor available Previous participation stem cell study within last 30 day</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Cord Blood</keyword>
	<keyword>Stem Cells</keyword>
	<keyword>MPC</keyword>
	<keyword>Mesoblast</keyword>
	<keyword>Expanded</keyword>
	<keyword>AML</keyword>
	<keyword>ALL</keyword>
	<keyword>NHL</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Lymphoma</keyword>
</DOC>